Keeping science on top in drug evaluation.
Avorn
Jerry
J
Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Boston, USA.
D026683:Advisory Committees; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016265:Conflict of Interest; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D020372:Dexfenfluramine / Q000009:adverse effects; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004341:Drug Evaluation / Q000592:standards*; D004345:Drug Industry; D000077613:Etoricoxib; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007783:Lactones / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D012306:Risk; D000077154:Rosiglitazone; D013450:Sulfones / Q000009:adverse effects; D045162:Thiazolidinediones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics / Q000592:standards*
D016861:Cyclooxygenase Inhibitors; D007004:Hypoglycemic Agents; D007783:Lactones; D011725:Pyridines; D013450:Sulfones; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C116926:rofecoxib; D020372:Dexfenfluramine; D000077613:Etoricoxib